Trial · NCT04612725
Participant flow25
How many started, completed or left each group, period by period.
1 to 20 of 25
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Double-blind Then Extension Period: Benralizumab 30 mg Q4W | 30 | |
| Overall Study | STARTED | Double-blind Then Extension Period: Benralizumab 30 mg Q8W | 29 | |
| Overall Study | STARTED | Double-blind Then Extension Period: Benralizumab 60 mg Q4W | 28 | |
| Overall Study | STARTED | Double-blind Then Extension Period: Benralizumab 60 mg Q8W | 28 | |
| Overall Study | STARTED | Double-blind Then Extension Period: Placebo | 40 | |
| Overall Study | Completed the Treatment Period | Double-blind Then Extension Period: Benralizumab 30 mg Q4W | 26 | |
| Overall Study | Completed the Treatment Period | Double-blind Then Extension Period: Benralizumab 30 mg Q8W | 27 | |
| Overall Study | Completed the Treatment Period | Double-blind Then Extension Period: Benralizumab 60 mg Q4W | 25 | |
| Overall Study | Completed the Treatment Period | Double-blind Then Extension Period: Benralizumab 60 mg Q8W | 28 | |
| Overall Study | Completed the Treatment Period | Double-blind Then Extension Period: Placebo | 37 | |
| Overall Study | Entered Extension Period | Double-blind Then Extension Period: Benralizumab 30 mg Q4W | 24 | |
| Overall Study | Entered Extension Period | Double-blind Then Extension Period: Benralizumab 30 mg Q8W | 26 | |
| Overall Study | Entered Extension Period | Double-blind Then Extension Period: Benralizumab 60 mg Q4W | 25 | |
| Overall Study | Entered Extension Period | Double-blind Then Extension Period: Benralizumab 60 mg Q8W | 28 | |
| Overall Study | Entered Extension Period | Double-blind Then Extension Period: Placebo | 37 | |
| Overall Study | COMPLETED | Double-blind Then Extension Period: Benralizumab 30 mg Q4W | 16 | |
| Overall Study | COMPLETED | Double-blind Then Extension Period: Benralizumab 30 mg Q8W | 21 | |
| Overall Study | COMPLETED | Double-blind Then Extension Period: Benralizumab 60 mg Q4W | 20 | |
| Overall Study | COMPLETED | Double-blind Then Extension Period: Benralizumab 60 mg Q8W | 23 | |
| Overall Study | COMPLETED | Double-blind Then Extension Period: Placebo | 24 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04612725/flow